Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 145-151 , March 2010

Expression of potential molecular markers in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy

Received 28 May 2008 ,Revised 4 August 2008 ,Accepted 7 August 2008.

References 

  1. Amling CL. Biochemical recurrence after localized treatment. Urol Clin North Am. 2006;33:147–159
  2. Quinn DI, Henshall SM, Haynes AM, et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: Implications for staging systems and predictive models. J Clin Oncol. 2001;19:3692–3705
  3. Karakiewicz PI, Eastham JA, Graefen M, et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: Multi-institutional assessment of 5831 patients. Urology. 2005;66:1245–1250
  4. Kattan MW, Easthan JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771
  5. D'Amico AV, Whittington R, Kaplan I, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  6. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715–717
  7. Zellweger T, Ninck C, Bloch M, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer. 2005;113:619–628
  8. Freedland SJ, deGregorio F, Sacoolidge JC, et al. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol. 2003;169:1325–1330
  9. Inoue T, Segawa T, Shiraishi T, et al. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology. 2005;66:332–337
  10. Moul JW, Kane CJ, Malkowicz SB. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urol Clin North Am. 2001;28:459–472
  11. Walsh PC. Radical prostatectomy: A procedure in evolution. Semin Oncol. 1994;21:662–671
  12. Sakai I, Harada K, Hara I, et al. A comparison of the biological features between prostate cancers arising in the transition and peripheral zones. BJU Int. 2005;96:528–532
  13. Kurahashi T, Muramaki M, Yamanaka K, et al. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int. 2005;96:895–899
  14. Ramos CG, Roehl KA, Antenor JA, et al. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol. 2004;172:137–140
  15. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439–445
  16. Kurahashi T, Miyake H, Hara I, et al. Significance of Aurora-A expression in renal cell carcinoma. Urol Oncol. 2007;25:128–133
  17. Pettus JA, Weight CJ, Thompson CJ, et al. Biochemical failure in men following radical retropubic prostatectomy: Impact of surgical margin status and location. J Urol. 2004;172:129–132
  18. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferation rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol. 1998;110:443–449

PII: S1078-1439(08)00195-6

doi: 10.1016/j.urolonc.2008.08.001

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 2 , Pages 145-151 , March 2010

Article Tools

* Image Usage & Resolution